Page 7 - Maher Masoud News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Maher masoud. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Maher Masoud Today - Breaking & Trending Today

Investegate |MaxCyte, Inc. Announcements | MaxCyte, Inc.: Director Dealings and Issue of Equity

Gaithersburg, Maryland - 4 February 2021:

MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences company,
announces that further to the announcement of a £40 million (approx. $55 million) Subscription via a private placement of 5,740,000 new shares of common stock (the Subscription Announcement ) on 3 February, 2021, Doug Doerfler, Chief Executive Officer and a Founder of the Company, Ron Holtz, Senior Vice President and Chief Accounting Officer and J. Stark Thompson, Non-Executive Chairman, have exercised options in the amount of 755,000 shares of common stock, $0.01 par, of the Company ( Common Stock ) ( Exercise ) in aggregate. The 755,000 new shares of Common Stock issued pursuant to the Exercise ( New Options Common Stock ) have been sold by Doug Doerfler, Ron Holtz and J. Stark Thompson at a price of 700 pence per Common Stock ( Sale ). ....

United States , City Of , United Kingdom , Nick Adams , Doug Doerfler , Emma Earl , Chris Welsh , Duncan Monteith , James Black , Mary Jane Elliott , Freddy Crossley , Panmure Gordon , Ron Holtz , Rupert Dearden , Maxcyte Inc , London Stock Exchange , Company Is Maher Masoud , Founder Of The Company , Stifel Nicolaus Europe , Company Common Stock , Consilium Strategic Communications , Numis Securities , Chief Executive Officer , Senior Vice President , Chief Accounting Officer , Non Executive Chairman ,

Investegate |MaxCyte, Inc. Announcements | MaxCyte, Inc.: MaxCyte Announces £40 million Subscription

About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company s technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com. ....

New York , United States , United Kingdom , South Africa , City Of , Republic Of South Africa , Nick Adams , Duncan Monteith Matthew Odowd , Doug Doerfler , Amanda Murphy , Mary Jane Elliott Chris Welsh , Messers Doerfler , Emma Earl Freddy Crossley , Panmure Gordon , Ron Holtz , Rupert Dearden , Company Enlarged Share Capital , Company Annual , Directors Of The Company , Company Nominated Adviser , Companies As Casdin Capital , Company Or Stifel , None Of The Company , Maxcyte Inc , London Stock Exchange , Eu Which Is Part Of United Kingdom ,